Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation
Recruitment status was: Not yet recruiting
Escitalopram has been claimed to have the highest selectivity for the human serotonin transporter relative to the noradrenaline or dopamine transporters. This might be associated with greater clinical efficacy. Most adverse events reported by escitalopram-treated patients are mild and transient.
In this study, we compare escitalopram with placebo in the treatment of PE.
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study|
- change in geometric mean IELT from baseline to four weeks. [ Time Frame: 4 week ]
- changes in the intercourse satisfaction domain values of IIEF(Arabic version). Assessment of possible side effects [ Time Frame: 4 week ]
|Study Start Date:||May 2008|
|Estimated Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00656552
|Kasr el ainy school of medicine , Cairo university|
|Study Chair:||Hussein MH Ghanem, M D||Professor of Andrology & STDs|